Omnicell Inc (OMCL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Omnicell Inc (OMCL) has a cash flow conversion efficiency ratio of 0.025x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.35 Million) by net assets ($1.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Omnicell Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Omnicell Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Omnicell Inc total liabilities for a breakdown of total debt and financial obligations.
Omnicell Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Omnicell Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Far Eastern International Bank
TW:2845
|
-0.022x |
|
Israel Canada
TA:ISCN
|
-0.076x |
|
Fufeng Group Limited
F:FFO1
|
0.034x |
|
EMBOTELL. ANDINA ADR A/6
F:AKOA
|
N/A |
|
AUTOHOME INC. A DL -01
F:8AHA
|
N/A |
|
AT & S Austria Technologie & Systemtechnik Aktiengesellschaft
VI:ATS
|
0.210x |
|
Gelsenwasser AG
F:WWG
|
0.034x |
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
-2.317x |
Annual Cash Flow Conversion Efficiency for Omnicell Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Omnicell Inc from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see Omnicell Inc (OMCL) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.23 Billion | $127.30 Million | 0.103x | -31.55% |
| 2024-12-31 | $1.24 Billion | $187.72 Million | 0.151x | -0.87% |
| 2023-12-31 | $1.19 Billion | $181.09 Million | 0.152x | +121.31% |
| 2022-12-31 | $1.13 Billion | $77.78 Million | 0.069x | -65.95% |
| 2021-12-31 | $1.15 Billion | $231.81 Million | 0.202x | +5.23% |
| 2020-12-31 | $967.50 Million | $185.87 Million | 0.192x | +11.98% |
| 2019-12-31 | $845.25 Million | $145.01 Million | 0.172x | +12.14% |
| 2018-12-31 | $679.62 Million | $103.97 Million | 0.153x | +218.59% |
| 2017-12-31 | $517.20 Million | $24.83 Million | 0.048x | -56.77% |
| 2016-12-31 | $431.61 Million | $47.94 Million | 0.111x | +32.37% |
| 2015-12-31 | $402.39 Million | $33.76 Million | 0.084x | -49.77% |
| 2014-12-31 | $390.10 Million | $65.16 Million | 0.167x | +5.29% |
| 2013-12-31 | $348.33 Million | $55.26 Million | 0.159x | +23.59% |
| 2012-12-31 | $307.58 Million | $39.48 Million | 0.128x | +16.24% |
| 2011-12-31 | $282.91 Million | $31.24 Million | 0.110x | +42.33% |
| 2010-12-31 | $265.49 Million | $20.60 Million | 0.078x | -56.41% |
| 2009-12-31 | $242.30 Million | $43.13 Million | 0.178x | +112.81% |
| 2008-12-31 | $233.56 Million | $19.54 Million | 0.084x | -42.79% |
| 2007-12-31 | $254.64 Million | $37.23 Million | 0.146x | -32.55% |
| 2006-12-31 | $90.00 Million | $19.51 Million | 0.217x | +630.25% |
| 2005-12-31 | $55.24 Million | $-2.26 Million | -0.041x | +48.98% |
| 2004-12-31 | $53.70 Million | $-4.30 Million | -0.080x | -136.25% |
| 2003-12-31 | $34.76 Million | $7.68 Million | 0.221x | +204.60% |
| 2002-12-31 | $16.31 Million | $1.18 Million | 0.073x | +113.28% |
| 2001-12-31 | $19.60 Million | $-10.71 Million | -0.546x | -171.56% |
| 2000-12-31 | $-25.02 Million | $-19.11 Million | 0.764x | -- |
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for th… Read more